Stay updated with breaking news from Clinical Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SOUTH SAN FRANCISCO, Calif., May 21, 2024 -- Pliant Therapeutics, Inc. , a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment...
SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader...
Moderna (NASDAQ:MRNA) stock has collapsed from its all-time high. However, the company is once again on the move — in a good way. The stock is up 68% over the past six months, with partnerships around artificial intelligence (AI) and positive cancer trial data garnering investor interest. Personally, though, I’m still unconvinced that these developments make MRNA stock a buy and require more data before I make a decision. For now, I remain neutral. MRNA stock has fallen significantly from its al
Operator: Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.
Yesterday (April 29), Lonza, a global partner in the pharmaceutical, biotech, and nutraceutical sectors, announced the introduction of its AI-enabled Route Scouting Service (RSS).